About Antibiotics
Antibacterial drugs are chemical compounds used to kill or inhibit the growth of bacteria. The term "antibiotic" is often used synonymously with antibacterial; however, the term "antibiotic" was originally coined to refer to the antibacterial compounds of microbial origin. Antibacterial acts via various mechanisms such as the inhibition of cell wall synthesis, the inhibition of nucleic acid synthesis, the disruption of the cell membrane, and the inhibition of protein synthesis. It can be bacteriostatic or bactericidal in nature. Antibiotics are medicines that are used to treat infections caused by bacteria (e.g., respiratory tract infections). Antibiotics work against microorganisms such as bacteria, fungi, and parasites but are not effective against viruses. Antibiotics either block vital processes in bacteria, kill the bacteria, or halt them from growing. Antibiotics that affect a wide range of bacteria are called broad spectrum antibiotics (e.g., amoxicillin and gentamicin). Antibiotics that affect only a few types of bacteria are called narrow spectrum antibiotics (e.g., penicillin).
TechNavio's analysts forecast the Global Antibiotics market to grow at a CAGR of 1.41 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Antibiotics market for the period 2014–2018. To calculate the market size, the report considers the revenue generated from the sales of various antibiotics for human use. The Global Antibiotics market can be divided into eight segments: Beta-lactams, Macrolides, Aminoglycosides, Phenicols, Quinolones, Sulfonamides, Tetracyclines, and Others.
TechNavio's report, the Global Antibiotics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Antibiotics market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Eli Lilly
• GlaxoSmithKline
• Johnson & Johnson
• Novartis
• Pfizer
• Sanofi
Other Prominent Vendors
• Bayer HealthCare
• Bristol Myers Squibb
• Cubist Pharmaceuticals
• Daiichi Sankyo
• F. Hoffmann-La Roche
• Takeda Pharmaceutical
Market Driver
• Increased Aging Population
• For a full, detailed list, view our report
Market Challenge
• Emergence of Drug-resistant Strains
• For a full, detailed list, view our report
Market Trend
• Increase in Demand for Antibiotics
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01.Executive Summary
02.List of Abbreviations
03.Scope of the Report
03.1Market Overview
03.2Product Offerings
04.Market Research Methodology
04.1Market Research Process
04.2Research Methodology
05.Introduction
06.Market Landscape
06.1Market Overview
06.2Market Size and Forecast
06.3Antibiotics Market in the US
06.3.1Market Size and Forecast
06.4Antibiotics Market in Europe
06.4.1Market Size and Forecast
06.5Antibiotics Market in Asia
06.5.1Market Size and Forecast
06.6Five Forces Analysis
07.Market Segmentation by Mechanism of Action
07.1Introduction
08.Market Segmentation by Chemical Class
08.1Market Segmentation by Drug Origin
09.Geographical Segmentation
10.Buying Criteria
11.Market Growth Drivers
12.Drivers and their Impact
13.Market Challenges
14.Impact of Drivers and Challenges
15.Market Trends
16.Trends and their Impact
17.Vendor Landscape
17.1Competitive Scenario
17.1.1Key News
17.1.2Mergers and Acquisitions
17.2Market Share Analysis 2013
17.3Other Prominent Vendors
18.Key Vendor Analysis
18.1AstraZeneca plc
18.1.1Key Facts
18.1.2Business Description
18.1.3Business Segmentation
18.1.4Business Strategy
18.1.5Revenue by Business Segmentation
18.1.6Revenue Comparison 2011-2013
18.1.7Sales Revenue by Geographical Segmentation
18.1.8Key Developments
18.1.9SWOT Analysis
18.1.10Strengths
18.1.11Weaknesses
18.1.12Opportunities
18.1.13Threats
18.2GlaxoSmithKline plc
18.2.1Key Facts
18.2.2Business Overview
18.2.3Business Segmentation
18.2.4Business Segmentation by Revenue 2012 and 2013
18.2.5Sales by Geography
18.2.6Pipeline Products
18.2.7Business Strategy
18.2.8Key Information
18.2.9SWOT Analysis
18.2.10Strengths
18.2.11Weaknesses
18.2.12Opportunities
18.2.13Threats
18.3Eli Lilly and Co.
18.3.1Key Facts
18.3.2Business Overview
18.3.3Business Segmentation by Revenue 2013
18.3.4Business Segmentation by Revenue 2012 and 2013
18.3.5Sales by Geography
18.3.6Business Strategy
18.3.7Key Developments
18.3.8SWOT Analysis
18.3.9Strengths
18.3.10Weaknesses
18.3.11Opportunities
18.3.12Threats
18.4Johnson & Johnson
18.4.1Key Facts
18.4.2Business Overview
18.4.3Business Segmentation by Revenue 2013
18.4.4Business Segmentation by Revenue 2012 and 2013
18.4.5Geographical Segmentation by Revenue 2013
18.4.6Business Strategy
18.4.7Recent Developments
18.4.8SWOT Analysis
18.4.9Strengths
18.4.10Weaknesses
18.4.11Opportunities
18.4.12Threats
18.5Novartis AG
18.5.1Key Facts
18.5.2Business Overview
18.5.3Business Segmentation by Revenue 2013
18.5.4Business Segmentation by Revenue 2012 and 2013
18.5.5Sales by Geography
18.5.6Business Strategy
18.5.7Key Developments
18.5.8SWOT Analysis
18.5.9Strengths
18.5.10Weaknesses
18.5.11Opportunities
18.5.12Threats
18.6Pfizer Inc.
18.6.1Key Facts
18.6.2Business Description
18.6.3Business Segmentation
18.6.4Revenue by Business Segmentation
18.6.5Revenue Comparison 2012 and 2013
18.6.6Sales by Geography
18.6.7Business Strategy
18.6.8Key Developments
18.6.9SWOT Analysis
18.6.10Strengths
18.6.11Weaknesses
18.6.12Opportunities
18.6.13Threats
18.7Sanofi
18.7.1Key Facts
18.7.2Business Overview
18.7.3Business Segmentation by Revenue 2013
18.7.4Business Segmentation by Revenue 2012 and 2013
18.7.5Geographical Segmentation by Revenue 2013
18.7.6Business Strategy
18.7.7Key Developments
18.7.8SWOT Analysis
18.7.9Strengths
18.7.10Weakness
18.7.11Opportunities
18.7.12Threats
19.Other Reports in this Series
List of Exhibits
Exhibit 1:Market Research Methodology
Exhibit 2:Global Antibiotics Market 2013-2018 (US$ million)
Exhibit 3:Antibiotics Market in the US 2013-2018 (US$ million)
Exhibit 4:Antibiotics Market in Europe 2013-2018 (US$ million)
Exhibit 5:Antibiotics Market in Asia 2013-2018 (US$ million)
Exhibit 6:Challenges Related to Antibiotic Development
Exhibit 7:Global Antibiotics Market Segmentation by Mechanism of Action
Exhibit 8:Global Antibacterial Drugs Market Segmentation by Chemical Class
Exhibit 9:Cephalosporin Segmentation by Generation of Drugs
Exhibit 10:Global Antibacterial Drugs Market Revenue Segmentation by Chemical Class 2013
Exhibit 11:Global Antibacterial Drugs Market Segmentation by Chemical Class in Volume 2013
Exhibit 12:Global Antibacterial Drugs Market Segmentation by Drug Origin
Exhibit 13:Global Antibiotics Market by Geographical Segmentation 2013
Exhibit 14:J&J Market Sales by Therapeutic Area (Pharmaceuticals) 2013
Exhibit 15:J&J Market Sales by Major Franchise (Medical Devices and Diagnostics) 2013
Exhibit 16:Abbott Laboratories by Revenue 2013
Exhibit 17:AstraZeneca plc: Business Segmentation
Exhibit 18:AstraZeneca plc: Revenue by Business Segmentation2013
Exhibit 19:AstraZeneca plc: Revenue by Business Segmentation 2011-2013 (US$ billion)
Exhibit 20:AstraZeneca plc: Sales Revenue by Geographical Segmentation 2013
Exhibit 21:GlaxoSmithKline plc: Business Segmentation 2013
Exhibit 22:GlaxoSmithKline plc: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 23:GlaxoSmithKline plc: Sales by Geography 2013
Exhibit 24:GlaxoSmithKline plc: Pipeline Products 2013
Exhibit 25:Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 26:Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 27:Eli Lilly and Co.: Sales by Geography 2013
Exhibit 28:Johnson & Johnson: Business Segmentation by Revenue 2013
Exhibit 29:Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 30:Johnson & Johnson: Geographical Segmentation by Revenue 2013
Exhibit 31:Novartis AG: Business Segmentation by Revenue 2013
Exhibit 32:Novartis AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 33:Novartis AG: Sales by Geography 2013
Exhibit 34:Pfizer Inc.: Business Segmentation
Exhibit 35Pfizer Inc.: Revenue by Business Segmentation 2013
Exhibit 3:Pfizer Inc.: Revenue by Business Segmentation 2012 and 2013
Exhibit 37:Pfizer Inc.: Revenue by Geography 2013
Exhibit 38:Sanofi: Business Segmentation by Revenue 2013
Exhibit 39:Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 40:Sanofi: Geographical Segmentation by Revenue 2013
